Gastrointestinal Cancer

For patients with NRG1+ cholangiocarcinoma, zenocutuzumab may be a therapy option, according to results from the phase 2 eNRGY trial.

The overall survival benefit with the bemarituzumab combination in the phase 3 FORTITUDE-101 trial was consistent across key prespecified subgroups.

Data from the STELLAR-303 trial support zanzalintinib plus atezolizumab as a potential chemotherapy-free option in previously treated metastatic CRC.

The safety profile of telisotuzumab adizutecan was manageable in pancreatic ductal adenocarcinoma, consistent with its profile in other tumor types.

Findings from the DeFianCe trial support further development of sirexatamab in DKK1-high previously treated metastatic colorectal cancer.

Patients with ESCC treated in 2 tislelizumab-based arms experienced higher composite complete response rates compared to chemoradiotherapy alone.

Overall survival data in the IMbrave152/SKYSCRAPER-14 study are not anticipated to show statistical significance.

Data from the INTERCEPT study support ctDNA clearance as a useful end point for potential benefit in studies assessing novel therapeutics.

ITM-11 showed superior PFS and ORR compared with everolimus in patients with gastroenteropancreatic neuroendocrine tumors.

XTR008 achieved a higher ORR and improved QOL compared with high-dose octreotide long-acting repeatable in advanced GEP-NETs.

A numerically greater response rate with regorafenib/nivolumab may encourage a search for more non-chemotherapy combinations for gastric cancer.

A survival analysis stratified by demographic and clinical characteristics revealed an OS benefit was observed with across key subgroups.

Meta: Safety outcomes, including the treatment-related AEs and AEs leading to treatment discontinuation, were consistent with or without lenvatinib in ESCC.

Serious AEs occurred in 49% of patients treated with FOLFIRNOX vs 43% of patients treated with chemoradiation for pancreatic ductal adenocarcinoma.

Investigators are actively enrolling patients with locally advanced rectal cancer in the phase 1b FORTRESS trial evaluating NG-350A plus chemotherapy.

Raed M. Al-Rajabi, MD, discussed the state of immune effector cell therapy for GI malignancies following a presentation he gave at the 2025 ICE-T Congress.

Survival results were similar among all patients and PD-L1 subgroups with the domvanalimab regimen in gastroesophageal junction adenocarcinoma.

A manageable safety profile and survival benefit was observed across patient groups with somatostatin receptor–positive GEP-NETs.

Atebimetinib with gemcitabine and nab-paclitaxel achieved 9-month OS and PFS of 86% and 53%, respectively, in patients with pancreatic cancer in frontline settings.

At 30 months, mitazalimab plus mFOLFIRINOX achieved an OS rate of 21% in patients with previously untreated metastatic PDAC.

New therapies for hepatobiliary cancers show promise, expanding treatment options for patients with advanced disease and challenging conditions.

Patients with PDAC and non-GOF mutations had less favorable OS and DFS outcomes in various instances compared with those who had wild-type genes or GOF mutations.

An independent data monitoring committee recommended the continuation of the phase 2 AMPLIFY-7P trial evaluating ELI-002 7P in PDAC in August 2025.

The test may help identify patients with microsatellite instability-high colorectal cancer who benefit from nivolumab therapy alone or with ipilimumab.

The performance of the latest Shield algorithm underwent validation in an expanded cohort of individuals enrolled on the ECLIPSE study.

In patients with rectal cancer, the median OS was 12 years in the chemotherapy and radiation therapy group vs 24 years in the chemotherapy alone group.

Decreased MAPK signature and increased interferon gamma response signature were associated with sustained treatment benefit on serial evRNA profiling.

The incidence of grade 3 to 4 acute toxicities was similar in patients with high-risk gastric cancer treated with chemoradiation or chemotherapy.

The addition of dendritic cells to TACE in patients with intermediate-stage HCC did not significantly increase the incidence or severity of AEs.